Editor's letter

Welcome to the latest issue of Pharmaceutical Technology Focus magazine

With initiatives at the US Food and Drug Administration (FDA) and other events competing for attention, it is unclear what the future of rare disease research under the Trump administration will be.

This month's cover story examines what factors are at play in driving rare disease research in the US, or hindering its momentum.

Also in this issue, we look at how RFK Jr's vaccine dream in the US is liable to play out. Another feature looks at the EU's pharma regulation reforms.

Don’t miss our round up feature on what was shared during this year's Clinical Trials in Oncology (CTO) conference in Boston.

All this and the latest pharma industry news, comment, and analysis from GlobalData.

Ross Law, deputy editor